Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Considerations in reviewing network meta-analyses of heterogeneous clinical trial designs: a methodological review in Crohn's disease and ulcerative colitis.

Crohn's & colitis 360·2026
Same author

Upfront medical or surgical treatment in Crohn's disease.

The lancet. Gastroenterology & hepatology·2026
Same author

Ultrasound criteria for transmural healing and response in Crohn's disease: a systematic review of definitions and thresholds.

Inflammatory bowel diseases·2026
Same author

A Method to Enrich Functional Human Paneth Cells in Induced Pluripotent Stem Cell-Derived Intestinal Organoids.

Cellular and molecular gastroenterology and hepatology·2026
Same author

A blood-based transcriptomic signature stratifies severe Crohn's disease and defines potentially targetable therapeutic pathways.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

Genomic Insights Into Inflammatory Bowel Disease in United States Hispanic Participants: An Ancestry-Focused Study.

Gastroenterology·2026
Same journal

Engineering immune cell therapies for inflammatory bowel disease: from stem cells to CAR T cells.

Nature reviews. Gastroenterology & hepatology·2026
Same journal

Actin cytoskeletal dynamics in hepatic myofibroblasts and fibrosis.

Nature reviews. Gastroenterology & hepatology·2026
Same journal

Synthetic data generation: challenges and perspectives for gastrointestinal medicine.

Nature reviews. Gastroenterology & hepatology·2026
Same journal

Steatotic liver disease in Latin America: current views and perspectives.

Nature reviews. Gastroenterology & hepatology·2026
Same journal

Positive results for daraxonrasib for previously treated metastatic pancreatic cancer.

Nature reviews. Gastroenterology & hepatology·2026
Same journal

Dietary perturbation and microbial adaptation in the gut.

Nature reviews. Gastroenterology & hepatology·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Future biologic targets for IBD: potentials and pitfalls.

Gil Y Melmed1, Stephan R Targan

  • 1Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, 8635 West 3rd Street, 960-W Los Angeles, CA 90048, USA. melmedg@cshs.org

Nature Reviews. Gastroenterology & Hepatology
|February 6, 2010
PubMed
Summary
This summary is machine-generated.

Biologic therapies target specific immune abnormalities in inflammatory bowel disease (IBD). Identifying patient subsets with genetic or immunologic markers can improve future biologic drug development and treatment efficacy.

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Experiment Videos

Last Updated: Jun 16, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Inflammatory bowel disease (IBD) treatment increasingly utilizes biologic therapies.
  • Biologics target specific molecular and cellular immune abnormalities.
  • Genetic factors significantly influence IBD susceptibility and immune pathway alterations.

Purpose of the Study:

  • To review the evolution of biologic therapy in IBD.
  • To highlight the role of immune pathways, like IL-12-IL-23, in IBD pathogenesis and drug targeting.
  • To discuss lessons learned from therapeutic drug trials and future directions.

Main Methods:

  • Literature review of IBD pathogenesis and treatment strategies.
  • Analysis of genetic associations with IBD and immune pathway involvement.
  • Evaluation of insights from failed clinical trials.

Main Results:

  • Multiple genes linked to IBD susceptibility affect immune pathways.
  • The IL-12-IL-23 pathway is a key target for IBD drug development.
  • Analysis of failed trials reveals issues in study design, drug delivery, and assessment.

Conclusions:

  • Understanding immune pathways is crucial for IBD pathogenesis and novel drug targets.
  • Biologic drug development requires early identification of patient responders using biomarkers.
  • Future IBD treatments will benefit from personalized approaches based on genetic and immunologic profiles.